Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Streptococcal Pneumonia Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Streptococcal Pneumonia Overview | 13 | 1 |
| Pipeline Products for Streptococcal Pneumonia Comparative Analysis | 14 | 1 |
| Streptococcal Pneumonia Therapeutics under Development by Companies | 15 | 2 |
| Streptococcal Pneumonia Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Streptococcal Pneumonia Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Streptococcal Pneumonia Products under Development by Companies | 21 | 2 |
| Streptococcal Pneumonia Products under Investigation by Universities/Institutes | 23 | 1 |
| Streptococcal Pneumonia Companies Involved in Therapeutics Development | 24 | 28 |
| Abera Bioscience AB | 24 | 1 |
| Actelion Ltd | 25 | 1 |
| Alvogen Korea Co., Ltd. | 26 | 1 |
| Arsanis Biosciences GmbH | 27 | 1 |
| AstraZeneca Plc | 28 | 1 |
| Beijing Minhai Biotechnology Co., Ltd | 29 | 1 |
| ContraFect Corporation | 30 | 1 |
| Daiichi Sankyo Company, Limited | 31 | 1 |
| Eurocine Vaccines AB | 32 | 1 |
| FluGen, Inc. | 33 | 1 |
| GlaxoSmithKline Plc | 34 | 1 |
| ImmunoBiology Limited | 35 | 1 |
| Lascco SA | 36 | 1 |
| Liquidia Technologies, Inc. | 37 | 1 |
| Merck &Co., Inc. | 38 | 1 |
| Mucosis B.V. | 39 | 1 |
| Panacea Biotec Limited | 40 | 1 |
| Prometheon Pharma, LLC | 41 | 1 |
| Sanofi Pasteur SA | 42 | 1 |
| Serum Institute of India Limited | 43 | 1 |
| SK Chemicals Co., Ltd. | 44 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 45 | 1 |
| Valneva SE | 46 | 1 |
| Vaxxilon AG | 47 | 1 |
| Virometix AG | 48 | 1 |
| Walvax Biotechnology Co., Ltd. | 49 | 1 |
| Wellstat Vaccines, LLC | 50 | 1 |
| Wockhardt Limited | 51 | 1 |
| Streptococcal Pneumonia Therapeutics Assessment | 52 | 10 |
| Assessment by Monotherapy Products | 52 | 1 |
| Assessment by Combination Products | 53 | 1 |
| Assessment by Target | 54 | 2 |
| Assessment by Mechanism of Action | 56 | 2 |
| Assessment by Route of Administration | 58 | 2 |
| Assessment by Molecule Type | 60 | 2 |
| Drug Profiles | 62 | 58 |
| (Streptococcal pneumonia + typhoid) vaccine - Drug Profile | 62 | 1 |
| Product Description | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| R&D Progress | 62 | 1 |
| Ab-01 - Drug Profile | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 1 |
| ACT-292706 - Drug Profile | 64 | 1 |
| Product Description | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| R&D Progress | 64 | 1 |
| ACT-387042 - Drug Profile | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 1 |
| ASN-400 - Drug Profile | 66 | 1 |
| Product Description | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| R&D Progress | 66 | 1 |
| AZ-6142 - Drug Profile | 67 | 1 |
| Product Description | 67 | 1 |
| Mechanism of Action | 67 | 1 |
| R&D Progress | 67 | 1 |
| CAL-02 - Drug Profile | 68 | 1 |
| Product Description | 68 | 1 |
| Mechanism of Action | 68 | 1 |
| R&D Progress | 68 | 1 |
| CF-303 - Drug Profile | 69 | 1 |
| Product Description | 69 | 1 |
| Mechanism of Action | 69 | 1 |
| R&D Progress | 69 | 1 |
| CF-309 - Drug Profile | 70 | 1 |
| Product Description | 70 | 1 |
| Mechanism of Action | 70 | 1 |
| R&D Progress | 70 | 1 |
| DEF-201 - Drug Profile | 71 | 1 |
| Product Description | 71 | 1 |
| Mechanism of Action | 71 | 1 |
| R&D Progress | 71 | 2 |
| GSK-2189242A - Drug Profile | 73 | 1 |
| Product Description | 73 | 1 |
| Mechanism of Action | 73 | 1 |
| R&D Progress | 73 | 1 |
| LCB-010371 - Drug Profile | 74 | 1 |
| Product Description | 74 | 1 |
| Mechanism of Action | 74 | 1 |
| R&D Progress | 74 | 2 |
| Monoclonal Antibodies for Pneumococcus Infections - Drug Profile | 76 | 1 |
| Product Description | 76 | 1 |
| Mechanism of Action | 76 | 1 |
| R&D Progress | 76 | 1 |
| Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile | 77 | 1 |
| Product Description | 77 | 1 |
| Mechanism of Action | 77 | 1 |
| R&D Progress | 77 | 1 |
| Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Neurodegenerative Diseases - Drug Profile | 78 | 1 |
| Product Description | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| R&D Progress | 78 | 1 |
| NBP-606 - Drug Profile | 79 | 1 |
| Product Description | 79 | 1 |
| Mechanism of Action | 79 | 1 |
| R&D Progress | 79 | 1 |
| Nucovac - Drug Profile | 80 | 1 |
| Product Description | 80 | 1 |
| Mechanism of Action | 80 | 1 |
| R&D Progress | 80 | 1 |
| PneuGEM - Drug Profile | 81 | 1 |
| Product Description | 81 | 1 |
| Mechanism of Action | 81 | 1 |
| R&D Progress | 81 | 1 |
| pneumococcal (13-valent) vaccine - Drug Profile | 82 | 1 |
| Product Description | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| R&D Progress | 82 | 1 |
| pneumococcal (13-valent) vaccine - Drug Profile | 83 | 1 |
| Product Description | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| R&D Progress | 83 | 1 |
| pneumococcal (13-valent) vaccine - Drug Profile | 84 | 1 |
| Product Description | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| R&D Progress | 84 | 1 |
| pneumococcal (23-valent) vaccine - Drug Profile | 85 | 1 |
| Product Description | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| R&D Progress | 85 | 1 |
| pneumococcal (23-valent) vaccine - Drug Profile | 86 | 1 |
| Product Description | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| R&D Progress | 86 | 1 |
| pneumococcal [serotype 4, 6A] vaccine - Drug Profile | 87 | 1 |
| Product Description | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| R&D Progress | 87 | 1 |
| pneumococcal [strain TIGR4] vaccine - Drug Profile | 88 | 1 |
| Product Description | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| R&D Progress | 88 | 1 |
| pneumococcal vaccine - Drug Profile | 89 | 1 |
| Product Description | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| R&D Progress | 89 | 1 |
| pneumococcal vaccine - Drug Profile | 90 | 1 |
| Product Description | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| R&D Progress | 90 | 1 |
| pneumococcal vaccine - Drug Profile | 91 | 1 |
| Product Description | 91 | 1 |
| Mechanism of Action | 91 | 1 |
| R&D Progress | 91 | 1 |
| pneumococcal vaccine - Drug Profile | 92 | 1 |
| Product Description | 92 | 1 |
| Mechanism of Action | 92 | 1 |
| R&D Progress | 92 | 1 |
| pneumococcal vaccine - Drug Profile | 93 | 1 |
| Product Description | 93 | 1 |
| Mechanism of Action | 93 | 1 |
| R&D Progress | 93 | 1 |
| pneumococcal vaccine - Drug Profile | 94 | 1 |
| Product Description | 94 | 1 |
| Mechanism of Action | 94 | 1 |
| R&D Progress | 94 | 1 |
| pneumococcal vaccine - Drug Profile | 95 | 1 |
| Product Description | 95 | 1 |
| Mechanism of Action | 95 | 1 |
| R&D Progress | 95 | 1 |
| pneumococcal vaccine - Drug Profile | 96 | 1 |
| Product Description | 96 | 1 |
| Mechanism of Action | 96 | 1 |
| R&D Progress | 96 | 1 |
| PneumoMab - Drug Profile | 97 | 1 |
| Product Description | 97 | 1 |
| Mechanism of Action | 97 | 1 |
| R&D Progress | 97 | 1 |
| pneumonia vaccine - Drug Profile | 98 | 1 |
| Product Description | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| R&D Progress | 98 | 1 |
| PnuBioVax - Drug Profile | 99 | 1 |
| Product Description | 99 | 1 |
| Mechanism of Action | 99 | 1 |
| R&D Progress | 99 | 1 |
| PPV-23 - Drug Profile | 100 | 1 |
| Product Description | 100 | 1 |
| Mechanism of Action | 100 | 1 |
| R&D Progress | 100 | 1 |
| SIILPCV-10 - Drug Profile | 101 | 1 |
| Product Description | 101 | 1 |
| Mechanism of Action | 101 | 1 |
| R&D Progress | 101 | 1 |
| SM-295291 - Drug Profile | 102 | 1 |
| Product Description | 102 | 1 |
| Mechanism of Action | 102 | 1 |
| R&D Progress | 102 | 1 |
| SM-369926 - Drug Profile | 103 | 1 |
| Product Description | 103 | 1 |
| Mechanism of Action | 103 | 1 |
| R&D Progress | 103 | 1 |
| Small Molecule for Respiratory Tract Infections - Drug Profile | 104 | 1 |
| Product Description | 104 | 1 |
| Mechanism of Action | 104 | 1 |
| R&D Progress | 104 | 1 |
| Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile | 105 | 1 |
| Product Description | 105 | 1 |
| Mechanism of Action | 105 | 1 |
| R&D Progress | 105 | 1 |
| Small Molecules for Streptococcus Pneumoniae Infections - Drug Profile | 106 | 1 |
| Product Description | 106 | 1 |
| Mechanism of Action | 106 | 1 |
| R&D Progress | 106 | 1 |
| Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile | 107 | 1 |
| Product Description | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| R&D Progress | 107 | 1 |
| streptococcal pneumonia vaccine - Drug Profile | 108 | 1 |
| Product Description | 108 | 1 |
| Mechanism of Action | 108 | 1 |
| R&D Progress | 108 | 1 |
| Streptococcal pneumonia vaccine - Drug Profile | 109 | 1 |
| Product Description | 109 | 1 |
| Mechanism of Action | 109 | 1 |
| R&D Progress | 109 | 1 |
| Streptococcal pneumonia vaccine - Drug Profile | 110 | 1 |
| Product Description | 110 | 1 |
| Mechanism of Action | 110 | 1 |
| R&D Progress | 110 | 1 |
| Streptococcal pneumonia vaccine 3 - Drug Profile | 111 | 1 |
| Product Description | 111 | 1 |
| Mechanism of Action | 111 | 1 |
| R&D Progress | 111 | 1 |
| Streptococcus pneumonia (whole-cell) vaccine - Drug Profile | 112 | 1 |
| Product Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| R&D Progress | 112 | 2 |